The majority of nucleoside-naive patients with chronic hepatitis B who took Bristol-Myers Squibb's entecavir for at least three years "achieved substantial histologic improvement and regression of fibrosis or cirrhosis" during a company-sponsored study. The study involved 69 patients from two late-stage trials of entecavir.

Full Story:
Modern Medicine

Related Summaries